Connect with us

For inquiry and send press release please email us to : info@ksajournal.com

Health

What you need to know before taking weight-loss drugs

Weight-loss drugs are not the quick fix solution that many people believe, especially if you hope to keep the pounds off in the long-term.

Sarah Le Brocq has direct experience of the transformative effects of weight-loss drugs. She has lived with obesity for most of her adult life and tried numerous diets. “Anything that came out, I thought, ‘I’ll try that because that might work for me’.” Unfortunately, the weight always came back, she told the BBC’s Inside Health.

After taking weight-loss drugs for more than two years, she has lost almost eight stone (51kg/112lb). “All of a sudden I wasn’t thinking about food anymore,” she says. “I’ve just got more energy, I’m doing things I couldn’t do before… it’s kind of given me a new freedom in life again.”

Millions of people like Sarah are now accessing medications like semaglutide and tirzepatide, better known by their popular brand names Ozempic and Mounjaro. The numbers of people on weight-loss medication is only likely to increase as new drugs appear on the market too, including pills rather than the current jabs.

It’s clear that these drugs are opening up a new era in the treatment of obesity. The condition, is now a “mitigatable” issue, David Cummings, professor of medicine at the University of Washington tells me. “They are the closest thing I’ve seen to miracle drugs”. 

Other academics, however, warn that we risk losing sight of the need for behavioural change, especially as weight tends to be regained quickly when people stop taking the drugs.

So what should anyone planning to use weight-loss medication consider before they start?

How they work

Weight-loss drugs work by suppressing an individual’s appetite by mimicking hormones that tell our body when it is full. The most common are known as glucagon-like peptide 1, or GLP-1, and glucose-dependent insulinotropic polypeptide, or GIP.

The drugs bind to specialised molecules on the surface of our cells known as GLP-1 and GIP receptors, which play a key role in telling our body when it has had enough food.

Typically someone taking these drugs will begin to lose weight within the first few weeks. Although the drugs are only approved for weight loss in people with obesity, there is a rapidly growing private market for those not considered clinically obese.

Their popularity has been rising because they are extremely effective, with weight loss of between 14-20% in 72 weeks. But about 10-15% of people lose very little weight, so called “non-responders“.

GLP-1s are like “a chemical shield” that protects individuals against our “modern obesogenic environment, filled with cheap, calorie-dense foods”, says Naveed Sattar, a professor of cardiometabolic medicine at the University of Glasgow and leads the UK Government’s Obesity Healthcare Goals programme. He has also consulted on medical trials with several companies who produce weight-loss drugs but does not own any shares.

“There’s food everywhere,” he says – and within half an hour anyone “can pick up the phone and order 10,000 calories of food”.

If you stop, you’ll gain weight

If someone living with obesity starts to take weight-loss drugs, they need to consider that they may be on the drug long-term, says Cummings, who runs a weight management programme for individuals with obesity who have BMIs of 50 and above.

A common question he is asked by his patients before they start taking a weight-loss drug is how long they will be on it. Typically, they stop taking the drugs after about a year, he says. One analysis of scientific studies involving more than 9,000 patients indicated the average treatment duration was 39 weeks. People believe they can continue to lose weight using their willpower, he says, but the evidence suggests that is not the case.

People stop for various reasons, either due to the expense of treatment, their insurers stopping coverage or individuals not wishing to be on drugs for a prolonged period of time, Cummings has found.

And when people do stop the drugs, their weight tends to rebound. A recent study found that weight regain happens up to four times more quickly after stopping weight-loss drugs compared to someone ending a weight-loss programme that focuses on changing their behaviour.

Another study found that those on weight-loss drugs gained 1.5kg (3.3lbs) eight weeks after they stopped the medication, with their weight continuing to climb with the more time that passed. The same study also found that other health concerns, such as high blood pressure, also returns. New research has also found that people who stop taking weight-loss drugs gain back around 60% of the weight they lost a year later.

It returns quickly because of something researchers call “food noise“, which consists of persistent and intrusive thought around food, says Sattar.

Hormones play a role too. When an individual tries to lose weight, it triggers a powerful hormonal response that tells your body to regain the weight you lost. Cummings explains that because of this, the brain interprets a calorie drop as an energy deficiency, so after stopping weight-loss drugs, hormones that stimulate appetite increase while the rate at which you burn energy – the metabolic rate – decreases. “If these biological defences are strong enough, they can blunt the drug’s effectiveness,” he says.

Lifestyle change

Sattar has observed that for a small proportion of people who make lifestyle changes, it may be possible to reduce the dose or use the drug intermittently instead. Some really do make “fundamental changes in their diet”, he says.

“Others might need it at a lower dose than they would when they started. But the majority will probably still need some dose of the drug because the [food] environment is still the same.”

There’s also increasing concern that individuals are taking weight-loss medication as a substitute for making life-style changes – even though evidence shows that modifying lifestyle in combination with weight-loss drugs is what will lead to greater weight loss.

Experts have recently cautioned in a scientific review of the evidence that when there’s a lack of behavioural and lifestyle support for those on weight-loss drugs, it can leave individuals vulnerable to nutritional deficiencies. “We need to make sure people are getting enough protein and are getting all the vitamins and minerals they need,” says Marie Spreckley a nutrition and behavioural scientist at Cambridge University and lead author of the report. “You don’t want to have longer-term unintended consequences, like frailty and muscle loss. We don’t want to replace one health concern with another.”

Because these medications cause a dramatic appetite reduction, patients tend to eat less overall, she and her colleagues note. This can lead to a “missed opportunity” if patients are not supported long-term and their food choices remain poor.

No quick fix

The World Health Organization has therefore stated that medication alone won’t “reverse the obesity challenge”. Early interventions, screening and creating healthier environments are also needed, the organisation has stated in its guidelines on using GLP-1 drugs.

This is easier when people are still taking the drugs, Sattar says. “You have more mental space to think about your diet.”

But behavioural change is extremely challenging, says Amanda Daley, a professor of behavioural medicine at Loughborough University in the UK. She says there needs to be better communication with patients about how quickly they can regain weight once they stop taking GLP-1 medication.

Obesity is a chronic, relapsing condition, she says, which means it cannot be “cured” with a drug alone. That’s why additional support and “wraparound care” is key to ensure patients make dietary changes as well as increasing their physical activity.

It’s unclear whether private providers are providing this crucial additional support, she says, which she finds concerning since so many people access the drugs privately and it is hard to monitor continuation of care.

Micro-nudges help change behaviour

To overcome some of this – researchers at Stanford have looked at how they can help support and encourage lifestyle changes. In one recent study, researchers tested whether small nudges – or “microsteps” – could help encourage healthy behavioural change for those taking GLP-1 medications.

The tiny changes focused on nutrition, physical activity, sleep and stress management. Crucially, the microsteps were small and manageable, such as swapping sugary drinks for water, no longer drinking coffee after lunch, taking a deep breath when stressed or popping outside for five minutes.

They found these helped improve behavioural expectations. It’s this “expectation” that’s a first necessary step for behavioural change, says Maya Adam, a clinical associate professor of paediatrics at Stanford School of Medicine, who was involved in the study.

“Achieving your best health involves a lot more than pharmacotherapy alone,” she says. “We found that giving people these little nudges may be very effective.” She calls these steps “too small to fail” because even small daily changes and habits make a real difference over time.

Side-effects

These kind of interventions are crucial to help give people the tools they need to enact change, Daley says, especially considering the known side effects. These include gastrointestinal issues. There has also been an observed increase in pancreatitis and gallstones. Muscle loss is another concern, especially among individuals who are not exercising. Recently a study found links to bone and joint conditions too.

While we now have several years of data on the effectiveness of GLP-1 drugs, we don’t yet know what the long-term outlook will be or whether the results will wear off over time. There is also a lack of data on how these drugs affect pregnancy outcomes or future generations, as the advice is not to take weight-loss drugs during pregnancy. 

But given the negative health outcomes for those living with obesity, the side effects pale in comparison, both Sattar and Cummings say. This is particularly the case for individuals with multiple weight-related conditions. Heart disease, cancer and stroke are the leading causes of death worldwide – and all are linked to obesity.

A changing landscape

What is clear is that the landscape for weight-loss medication is rapidly evolving.

There are other health benefits too beyond weight loss. In one major study involving two million people, the drugs were linked to better heart health, fewer infections, lower risk of drug abuse and lower incidences of dementia. It’s also been shown to improve sleep apnoea, arthritis and substance abuse. 

BBC

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

Fakeeh Health Achieves National Institute for Health Specialties (NIHS) Institutional Accreditation for Residency Training

Fakeeh Health Achieves Institutional Accreditation from the National Institute for Health Specialties (NIHS) for Residency Training

Dubai, UAE – 13 July 2026

Fakeeh Health has been awarded the Institutional Accreditation by the National Institute for Health Specialties (NIHS), reinforcing its position as one of the UAE’s academic healthcare providers and marking another important milestone in its commitment to postgraduate medical education and the development of future specialist physicians. Dr. Mohammed Al Houqani, Secretary General of NIHS, presented the Institutional Accreditation certificate to Fakeeh University Hospital (FUH), noting that this accreditation demonstrates FUH’s compliance with rigorous national standards in postgraduate medical education (PGME). He said he was delighted to see a private hospital actively contributing to healthcare workforce development, adding that academic hospitals play an important role in improving healthcare by integrating clinical care, education, research and continuous quality improvement. The accreditation has been awarded to Fakeeh Health, encompassing FUH together with its network of Fakeeh Medical Centers, recognizing the organization as an approved institution for PGME training in the United Arab Emirates. This achievement follows the successful accreditation of Fakeeh University Hospital’s Medical Internship Program.

The National Institute for Health Specialties (NIHS) is the UAE’s national authority responsible for regulating and accrediting postgraduate medical education and residency training. Institutions awarded NIHS Institutional Accreditation are recognized for meeting rigorous national standards in educational governance, faculty development, resident support, patient safety, clinical learning environments, quality improvement and competency-based medical education.

For Fakeeh Health, the accreditation represents far more than regulatory recognition. It reflects the strength of an integrated academic ecosystem designed to prepare the next generation of physicians through structured residency programs, multidisciplinary clinical exposure and a culture of continuous learning across its healthcare network.

The comprehensive accreditation process assessed multiple aspects of the organization’s educational framework, including institutional leadership and governance, faculty engagement, resident wellbeing, assessment systems, research opportunities, simulation-based education, patient safety, quality improvement initiatives and the overall clinical learning environment.

Since launching its postgraduate medical education programs in collaboration with Dubai Health Authority in 2021, Fakeeh Health has steadily expanded its academic portfolio. Through structured residency and internship programs, competency-based education, faculty development initiatives and simulation-enhanced learning, the organization continues to invest in preparing highly skilled physicians capable of meeting the evolving healthcare needs of the UAE.

Residents training within Fakeeh Health benefit from diverse clinical experiences across Fakeeh University Hospital and its network of Fakeeh Medical Centers, allowing them to gain exposure to primary, secondary and tertiary care while learning within a patient-centered environment that promotes teamwork, innovation and evidence-based practice.

The accreditation also supports the UAE’s long-term vision of developing a sustainable national healthcare workforce and further strengthens Dubai’s position as a regional centre for advanced medical education and specialist training.

Dr. Mazen Fakeeh, Chairman Fakeeh Health, said:

“At Fakeeh Health, we believe that shaping the future of healthcare begins with investing in people. Educating and mentoring the next generation of physicians is one of our greatest responsibilities, and this accreditation reflects years of commitment to building an academic environment where education, clinical excellence and innovation work together. We are proud to contribute to the UAE’s vision of developing a highly skilled healthcare workforce while continuing to raise the standards of medical education across the region.”

Dr. Mohaymen Abdelghany, Group CEO & Board Member Fakeeh Health, and CEO Fakeeh University Hospital, said::

“This accreditation is an achievement for every member of the Fakeeh Health family. It reflects the dedication of our physicians, educators, faculty members and support teams who have worked together to create an outstanding learning environment for future specialists. By investing in high-quality medical education today, we are helping shape the physicians who will care for the communities of tomorrow. We will continue expanding our academic programs, strengthening clinical training and creating opportunities that enable future healthcare professionals to thrive.”

Dr. Mazen Abou Chaaban, Designated Institutional Official (DIO), said:

“Institutional Accreditation is an important validation of the strength of our educational governance, faculty engagement and learning culture. More importantly, it confirms that we have created an environment where residents are supported academically, professionally and personally throughout their training. Our goal is not only to develop competent specialists, but also compassionate physicians who embrace lifelong learning, professionalism and patient-centered care.”

Fakeeh Health expressed its appreciation to the National Institute for Health Specialties for its guidance throughout the accreditation process and acknowledged the dedication of its physicians, faculty members, educators, administrators and support teams whose collective efforts made this achievement possible.

Looking ahead, Fakeeh Health will continue expanding its residency and postgraduate medical education programs while strengthening academic collaborations, research and innovation across its healthcare network. The organization remains committed to preparing the next generation of healthcare professionals and supporting the UAE’s ambition to become a global leader in healthcare, medical education and clinical excellence.

About Fakeeh Health

Fakeeh Health is an integrated academic healthcare network comprising Fakeeh University Hospital and a growing network of Fakeeh Medical Centers across the UAE. By combining world-class patient care with medical education, research and innovation, Fakeeh Health is committed to developing future healthcare professionals while delivering exceptional, patient-centered care across every stage of the healthcare journey.

Academic Excellence at a Glance

NIHS Institutional Accreditation for Residency Training

NIHS-accredited Medical Internship Program

More than 600 undergraduate healthcare students trained annually

Structured residency, internship and clinical training programmes

Strong partnerships with leading national and international universities and healthcare institutions

Ongoing commitment to developing the UAE’s future healthcare workforce

For more information please visit our website:

https://www.fakeeh.health
Continue Reading

Health

NMC Royal Hospital, Mohammed Bin Zayed City, Successfully Treats Lifelong Complications from Childhood Surgery

Advanced Reconstructive Surgery Helps Patient Regain Normal Urinary Function After Years of Complications

Abu Dhabi, UAE – A specialist urology team at NMC Royal Hospital, Mohammed Bin Zayed City, led by Dr. Rami Labib, Urologist, has successfully helped a 30-year-old patient regain normal urinary function after years of complications linked to a surgery he underwent as a child.

For many years, the patient experienced difficulty urinating and persistent urine leakage through small openings along the penis. The condition significantly affected his daily life, causing discomfort, embarrassment and a loss of confidence.

The complications were related to hypospadias, a condition present at birth in which the opening of the urethra is not located at the tip of the penis. While hypospadias is commonly corrected during childhood and most patients achieve excellent long-term results, a small number may develop complications later in life that require further treatment.

After a detailed assessment, Dr. Labib identified narrowing of the urethra, known as a urethral stricture, along with abnormal passages that were causing urinary leakage. Imaging tests confirmed the diagnosis and helped the team plan the most appropriate treatment.

To restore normal function, Dr. Labib performed a highly specialised reconstructive procedure known as a buccal mucosal graft urethroplasty. The surgery used a small piece of tissue taken from the inside of the patient’s cheek to rebuild the damaged section of the urethra and close the abnormal openings responsible for the leakage.

Commenting on the case, Dr. Rami Labib said:

“Patients who experience complications years after hypospadias repair often face significant physical and emotional challenges. Every case is different and requires careful planning to achieve the best outcome. Modern reconstructive techniques allow us to restore normal urinary function and help patients return to their daily lives with greater comfort and confidence.”

The operation was completed successfully, and the patient made a good recovery. During follow-up visits, he reported being able to urinate normally without any leakage and described a substantial improvement in his overall quality of life.

Expressing his gratitude, the patient said:

“After years of struggling with urinary problems following multiple surgeries, I can finally urinate normally again without any leakage. I am extremely grateful to Dr. Rami and the entire medical team for restoring my confidence and giving me my life back.”

Dr. Labib noted that advances in reconstructive urology continue to improve outcomes for patients with even the most complex conditions. With expert assessment, personalised treatment plans, and modern surgical techniques, many patients can achieve long-lasting relief and return to everyday activities with confidence.

About NMC Royal Hospital

NMC Royal Hospital is one of Abu Dhabi’s leading tertiary healthcare institutions, providing comprehensive medical and surgical services through highly specialised clinical teams and advanced technology. The hospital offers expertise across a wide range of specialties, including reconstructive urology, with a commitment to delivering safe, high-quality, patient-centred care.

Continue Reading

Health

Fakeeh University Hospital Brings New Hope to Patients with Complex Brain Conditions Through Advanced MRI-Guided Laser Neurosurgery

Russian teenager with high-risk brainstem tumour successfully undergoes minimally invasive laser treatment in Dubai

Dubai, UAE – June 2026 – Fakeeh University Hospital has successfully performed an advanced MRI-guided Laser Interstitial Thermal Therapy (LITT) procedure on a 15-year-old patient from Russia suffering from a brainstem glioma, one of the most challenging and high-risk brain tumours encountered in neurosurgery.

The young patient travelled to Dubai after conventional oncology treatments failed to halt the progression of the disease. The tumour, located deep within the brainstem, had caused progressive neurological deterioration, including worsening motor deficits and paralysis, significantly affecting his quality of life and presenting a complex therapeutic challenge.

Following extensive multidisciplinary discussions involving neurosurgery, neuro-oncology, radiology, and rehabilitation specialists, the medical team at Fakeeh University Hospital carefully evaluated all available treatment options. Given the tumour’s location within one of the most delicate regions of the brain, traditional open surgery was associated with exceptionally high risks.

The brainstem controls many of the body’s most vital functions, including movement, breathing, heart rate, and consciousness. Surgical intervention in this area has historically carried substantial risks, including permanent paralysis, respiratory failure, and even cardiac arrest.

To minimize these risks while offering a potential treatment option, the team elected to perform MRI-guided Laser Interstitial Thermal Therapy (LITT), a highly advanced minimally invasive neurosurgical technique increasingly used worldwide for carefully selected patients with deep-seated brain lesions.

The procedure was led by Dr. Tommaso Tufo, Consultant Neurosurgeon – Brain and Spine Surgery at Fakeeh University Hospital, using a stereotactic robotic-assisted approach. Through a small skin incision measuring only a few millimetres, a laser fibre was precisely implanted into the target area using advanced robotic guidance and neuronavigation technology.

The implantation phase lasted just over one hour, after which the patient was transferred to the MRI suite. Under continuous real-time MRI monitoring, laser thermal therapy was delivered over the course of approximately one to two hours, allowing surgeons to visualize the thermal effect in real time and precisely control the treatment zone throughout the procedure.

One of the most significant advantages of MRI-guided laser therapy is its ability to reach deep and difficult-to-access areas of the brain while minimizing disruption to surrounding healthy tissue. Real-time MRI thermal mapping provides exceptional precision, allowing surgeons to perform controlled volumetric reduction of tumours without the need for extensive surgical exposure.

Commenting on the case, Dr. Tommaso Tufo said:

“Brainstem tumours represent some of the most challenging conditions in neurosurgery because of their location within structures that control critical neurological and physiological functions. In this particular case, conventional treatment options had become limited, and traditional open surgery carried considerable risks. MRI-guided laser therapy allowed us to reach the lesion through a minimally invasive approach while maintaining a very high degree of precision and safety.”

He added:

“The successful treatment of this patient demonstrates the potential of modern laser neurosurgery to expand therapeutic options for carefully selected patients who may previously have had very limited alternatives. However, the true significance of this technology extends far beyond a single case.”

While the patient continues to undergo physiotherapy and additional oncological treatment as part of his ongoing care, he tolerated the procedure well and was able to resume mobility following treatment.

Dr. Tufo emphasized that MRI-guided Laser Interstitial Thermal Therapy should be viewed within the broader context of modern neurosurgery rather than as a solution limited to rare brainstem tumours.

“Laser neurosurgery represents an important advancement in the treatment of selected brain tumours, drug-resistant epilepsy, radiation necrosis, and other complex intracranial conditions,” he explained. “The technology allows us to treat lesions located deep within the brain through a very small incision while minimizing trauma to surrounding tissue. Both adult and pediatric patients may benefit from this approach when conventional surgery presents excessive risk.”

Historically, many patients with drug-resistant epilepsy required open cranial surgery to access and remove seizure-causing areas of the brain. Today, in selected cases, MRI-guided laser ablation offers a less invasive alternative that combines precision, safety, and shorter recovery times.

For appropriately selected patients, the minimally invasive nature of the procedure may significantly reduce hospitalization and recovery periods, with some individuals able to return home on the same day or within 24 hours. More complex cases, particularly those involving critical brain structures, may require extended monitoring to ensure optimal neurological recovery.

The introduction of advanced MRI-guided laser neurosurgery further strengthens Fakeeh University Hospital’s position as a regional center of excellence for complex neurological and neurosurgical care. By combining advanced imaging, robotic guidance, and minimally invasive techniques, the hospital continues to expand access to innovative treatment options for patients facing some of the most challenging brain conditions.

About Fakeeh University Hospital

Fakeeh University Hospital is a leading academic medical center located in Dubai Silicon Oasis and part of Fakeeh Health. The hospital combines advanced clinical care, medical education, research, innovation, and digital health technologies to deliver world-class healthcare services. Through continuous investment in cutting-edge medical technologies and multidisciplinary expertise, Fakeeh University Hospital remains committed to advancing patient care and improving outcomes across a wide range of complex medical conditions.

For more information, visit: Fakeeh Health – Advancing Healthcare with Excellence

Continue Reading

Trending